On December 18, 2025, President Donald Trump signed an executive order titled “Increasing Medical Marijuana and Cannabidiol Research,” directing Attorney General Pam Bondi to expedite the rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA). While the order does not itself accomplish the rescheduling, it represents the most significant federal cannabis policy development in decades and has profound implications for tax practitioners advising state-legal cannabis clients.
Executive Order Overview
The executive order directs the Attorney General to “take all necessary steps to complete the rulemaking process related to rescheduling marijuana to Schedule III of the CSA in the most expeditious manner in accordance with Federal law, including 21 U.S.C. 811.” This continues a process initiated under the Biden administration, which in May 2024 saw the Department of Justice propose a rule to reschedule marijuana. The proposal was based on a scientific and medical evaluation by the Department of Health and Human Services (HHS) finding that marijuana has currently accepted medical use for treating anorexia, nausea and vomiting, and pain.
Critical distinction: The executive order does not unilaterally reschedule marijuana. The president lacks authority to reschedule a controlled substance without following the formal rulemaking process under the CSA. However, the order signals clear executive intent to expedite completion of the regulatory process already underway.
IRC Section 280E: The Current Tax Burden
Internal Revenue Code Section 280E, enacted by Congress in 1982, prohibits businesses from deducting ordinary and necessary business expenses if they traffic in Schedule I or Schedule II controlled substances. The provision was a congressional response to the 1981 Tax Court decision in Edmondson v. Commissioner, which allowed a convicted drug trafficker to deduct business expenses under IRC Section 162.
Under current law, state-legal cannabis businesses face the following tax treatment:
- Allowed deductions: Cost of goods sold (COGS) only
- Disallowed deductions: All ordinary and necessary business expenses including payroll, rent, utilities, insurance, marketing, advertising, professional fees, and depreciation on assets not included in COGS
- Effective tax rates: Often 70% or higher, as tax is calculated on gross receipts minus COGS rather than on net income
Cannabis businesses are taxed on gross income rather than net income, creating substantially higher tax liabilities than similarly situated businesses in other industries. Industry analysis suggests the typical dispensary faces approximately $268,000 in annual federal tax burden attributable to Section 280E, with higher-volume locations experiencing burdens approaching $800,000 annually.
Cultivators versus retailers: The 280E burden falls disproportionately on retail operations. Cultivators can allocate more expenses to COGS (including direct labor, packaging, testing, and security directly related to production), while retailers have limited ability to increase their COGS deductions, resulting in higher effective tax rates for dispensaries.
Tax Impact of Rescheduling to Schedule III
Once marijuana is formally rescheduled to Schedule III, Section 280E will cease to apply to state-legal cannabis businesses. Schedule III substances are defined as drugs with moderate to low potential for physical and psychological dependence and include medications such as ketamine, buprenorphine, anabolic steroids, and Tylenol with codeine.
Post-rescheduling tax treatment:
- Cannabis businesses will be eligible to deduct ordinary and necessary business expenses under IRC Section 162, identical to any other industry
- Businesses will be able to claim depreciation deductions, potentially including bonus depreciation on qualifying property
- Section 174 research and experimentation costs will become relevant for businesses engaged in product development
- Federal business tax credits may become available where applicable
- Cannabis businesses should also be able to maximize the 199A QBI deduction, a PTET election, and even leverage the exception for accounting for inventory
Industry estimates suggest that eliminating Section 280E could unlock between $1.6 billion and $2.2 billion in incremental after-tax cash flow annually across the cannabis industry.
Critical Planning Issues and Open Questions
Effective Date Uncertainty
The most critical planning question is determining when Section 280E relief will become effective. The IRS has not yet issued guidance on this issue. Possible effective date scenarios include:
- Final rule publication date: Most conservative interpretation
- Beginning of tax year in which rescheduling occurs: Would provide relief for entire 2026 tax year if finalized in 2026
- Beginning of tax year following rescheduling: Would delay relief until 2027 for calendar-year taxpayers
Recommendation: Tax practitioners should monitor the Federal Register for the administrative hearing schedule and final rule publication. Given current timing, it appears likely that rescheduling will be finalized sometime in 2026, though whether relief applies to the full 2026 tax year or only to 2027 forward remains uncertain.
Retroactive Application
There is no indication that rescheduling will have a retroactive effect for tax purposes. Cannabis businesses should not expect relief from taxes paid under the Section 280E regime in prior years. The statute of limitations for filing refund claims (generally the later of three years from the date the return was filed or two years from the date the tax was paid) continues to run.
Protective claims: Practitioners representing clients who believe they have meritorious constitutional challenges to Section 280E should consider filing protective refund claims to preserve potential remedies, though such claims face significant legal hurdles given longstanding judicial validation of the statute.
Net Operating Loss Carryforwards
Cannabis businesses operating at an economic loss have been unable to recognize those losses for tax purposes due to Section 280E. Whether NOL carryforwards generated in years subject to Section 280E will become deductible in post-rescheduling years presents a complex question.
The argument for deductibility is that the loss was not deductible when incurred solely due to Section 280E’s prohibition. In the carryforward year, assuming Schedule III status, there is no prohibition limiting cannabis business deductions. However, this raises technical questions about whether losses that were never allowed can subsequently be recognized.
IRS guidance required: This issue requires explicit IRS guidance, as the interaction of prior-year 280E disallowances with post-rescheduling tax years presents novel questions.
Depreciation Recapture and Prior Disallowed Amounts
Cannabis businesses have placed substantial assets into service while subject to Section 280E, including real property, equipment, and intangibles. Key open questions include:
- Will businesses be permitted to claim catch-up depreciation for prior years when such deductions were disallowed under Section 280E?
- Will bonus depreciation be available for assets placed in service prior to rescheduling?
- How will Section 197 intangibles with unamortized basis be treated—catch-up amortization or prospective amortization only?
- What treatment will apply to capitalized Section 174 research costs?
The AICPA submitted a letter to Treasury and the IRS in October 2024 requesting guidance on these issues prior to rescheduling implementation.
Entity Structure Reconsideration
Many cannabis businesses elected C corporation status specifically to manage the punitive effects of Section 280E. Under Section 280E, pass-through entities faced particular challenges as higher taxable income at the gross profit level versus net profit level flowed through to the owners and the disallowed deductions reduced shareholder or partner basis causing tax implications upon the sale of the business.
Post-rescheduling, the traditional corporate tax rate of 21% plus individual tax on dividends may no longer be optimal for many cannabis businesses. Practitioners should evaluate:
- Whether conversion to pass-through status (S corporation or partnership) would result in lower overall tax burden
- Potential application of Section 199A qualified business income deduction for pass-through entities
- Potential tax savings from a PTET election for a pass-through entity
- Built-in gains tax implications for C to S corporation conversions
- State tax conformity issues, as some states have decoupled from Section 280E
State Tax Considerations
More than a dozen states have already decoupled from Section 280E for state tax purposes, allowing cannabis businesses operating legally under state law to deduct ordinary business expenses on state returns. These states include California, Connecticut, Delaware, New Jersey, New York, Virginia, and Washington, D.C.
Post-federal rescheduling, practitioners must monitor whether states that currently disallow full deductions will maintain that treatment or potentially reconsider their positions. States may need to update their conformity statutes or regulations related to Section 280E.
Estimated Tax Payment Adjustments
If rescheduling occurs during 2026, cannabis businesses will need to recalculate estimated tax payments for subsequent quarters. The elimination of Section 280E will dramatically reduce taxable income, potentially creating substantial overpayment scenarios for businesses that made estimated payments based on prior 280E calculations. Practitioners should prepare to file amended estimates and potentially seek quick refunds of overpayments.
What Rescheduling Does NOT Change
Tax practitioners should clearly communicate to cannabis clients that rescheduling to Schedule III:
- Does not legalize recreational cannabis: Cannabis remains a controlled substance under federal law, and possession, cultivation, and distribution remain federal crimes absent specific statutory exceptions
- Does not resolve banking access: Financial institutions remain subject to federal money laundering and Bank Secrecy Act requirements. The SAFER Banking Act or similar legislation would be required to provide comprehensive banking relief
- Does not eliminate state-federal conflicts: State-legal cannabis operations continue to violate the CSA, though federal enforcement priorities may evolve
- Does not mandate FDA pharmaceutical approval: State-regulated cannabis products do not become subject to FDA drug approval requirements; that pathway applies only to companies choosing to develop prescription drugs
Does not provide trademark protection: While rescheduling may open the door to federal trademark registrations previously denied, this remains uncertain pending USPTO guidance.
Immediate Action Items for Tax Practitioners
- Monitor DEA rulemaking process: Track Federal Register notices for hearing schedules, comment periods, and final rule publication
- Prepare for accounting method changes: Cannabis businesses may need to file Form 3115 applications for accounting method changes related to previously disallowed deductions
- Communicate timing uncertainty: Ensure clients understand that the executive order initiates a process but does not provide immediate relief
- Consider state tax impacts: Review state conformity statutes and monitor state-level guidance on treatment of cannabis deductions post-federal rescheduling
Update engagement letters: Consider whether cannabis client engagement letters should specifically address the evolving regulatory landscape and potential need for substantial tax planning adjustments during 2026.
Conclusion
President Trump’s December 18, 2025, executive order represents a watershed moment in federal cannabis policy with transformative implications for state-legal cannabis businesses. The elimination of IRC Section 280E’s punitive tax treatment has the potential to fundamentally alter the economics of the cannabis industry, improving cash flow, enabling reinvestment, and reducing the risk of business failures driven by unsustainable tax burdens.
However, significant uncertainties remain regarding implementation timing, treatment of prior-year tax positions, depreciation recapture, NOL carryforwards, and appropriate entity structures for post-280E planning. Tax practitioners advising cannabis clients should closely monitor IRS guidance development, prepare for multiple scenarios regarding effective dates, and proactively engage with clients on strategic planning opportunities that may have limited windows for implementation.
The formal rulemaking process will take time to complete, likely extending late into 2026. Practitioners should resist the temptation to make definitive representations to clients about tax treatment until the DEA publishes its final rule and the IRS issues implementing guidance. The administrative process remains subject to potential challenges, appeals, and procedural requirements that could affect timing.
This article is for informational purposes only and does not constitute legal or tax advice. Tax practitioners should conduct independent research and consult authoritative sources before advising clients on cannabis tax matters.